RUNX家族转录因子1在宫颈腺癌组织中的表达水平及其与患者预后的关系

doi:10.3969/j.issn.1004-616x.2025.03.003

Abstract

Abstract: OBJECTIVE： Cervical adenocarcinoma is markedly distinct from cervical squamous cell carcinoma due to its highly aggressive nature， lower response to radiotherapy， poor prognosis and reduced survival rates. This study aimed to investigate the expression level of RUNX1 in cervical adenocarcinoma tissues and its association with patient prognosis. METHODS： Tumor tissue samples from 37 cervical adenocarcinoma patients were collected. RUNX1 expression in tumor tissues was detected by immunohistochemistry (IHC)， and its correlation with clinicopathological parameters and prognosis was statistically analyzed. The Human Protein Atlas (HPA) database was used to analyze the protein expression level of RUNX1 in cervical adenocarcinoma tissues. Gene Set Variation Analysis (GSVA) scoring and the TIMER2.0 platform were utilized to perform signaling pathway enrichment and immune cell infiltration analyses， respectively， using cervical adenocarcinoma datasets from The Cancer Genome Atlas (TCGA) to preliminarily elucidate the mechanistic role of RUNX1 in cervical adenocarcinoma. RESULTS： Immunohistochemistry results demonstrated that RUNX1 expression in cervical adenocarcinoma showed significant differences correlated with patient prognosis and pathological stage (P<0.05). Patients in the RUNX1 high-expression group exhibited shorter overall survival and more advanced pathological stages. Analysis of the HPA database revealed that the protein expression level of RUNX1 was significantly higher than in normal cervical tissues. GSVA of cervical adenocarcinoma datasets from TCGA revealed that RUNX1 high expression was predominantly enriched in pathways including mitotic spindle assembly，Hedgehog signaling，TGF-β signaling，Wnt/β-catenin signaling， and p53 signaling. Immune cell infiltration analysis via TIMER2.0 indicated a significant correlation between RUNX1 expression and neutrophil infiltration. CONCLUSION： RUNX1 was found to be highly expressed in cervical adenocarcinoma and its overexpression was significantly associated with adverse prognosis，suggesting its potential as a prognostic biomarker for cervical adenocarcinoma patients.

Key words: cervical adenocarcinoma, RUNX1, prognosis, immune cell infiltration

CLC Number:

R737.33

GUO Ai, HUANG Ning, ZHANG Jing, ZHANG Yuanyuan, AN Jusheng, LIU Mei. Expression of RUNX family transcription factor 1 and its prognostic value in cervical adenocarcinomas[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 190-195.

References

[1] ZHENG W N, JIN F Y, WANG F, et al. Analysis of eEF1A2 gene expression and copy number in cervical carcinoma[J]. Medicine, 2023, 102(2): e32559.
[2] ARBYN M, WEIDERPASS E, BRUNI L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health, 2020, 8(2): e191-e203.
[3] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[4] ADEGOKE O, KULASINGAM S, VIRNIG B. Cervical cancer trends in the United States: a 35-year population-based analysis[J]. J Womens Health, 2012, 21(10): 1031-1037.
[5] GUO F J, COFIE L E, BERENSON A B. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction[J]. Am J Prev Med, 2018, 55(2): 197-204.
[6] RERUCHA C M, CARO R J, WHEELER V L. Cervical cancer screening[J]. Am Fam Physician, 2018, 97(7): 441-448.
[7] BEDELL S L, GOLDSTEIN L S, GOLDSTEIN A R, et al. Cervical cancer screening: past, present, and future[J]. Sex Med Rev, 2020, 8(1): 28-37.
[8] SMITH A J B, BEAVIS A L, ROSITCH A F, et al. Disparities in diagnosis and treatment of cervical adenocarcinoma compared with squamous cell carcinoma: an analysis of the national cancer database, 2004-2017[J]. J Low Genit Tract Dis, 2023, 27(1): 29-34.
[9] HODGSON A, PARK K J. Cervical adenocarcinomas: a heterogeneous group of tumors with variable etiologies and clinical outcomes[J]. Arch Pathol Lab Med, 2019, 143(1): 34-46.
[10] VAN DYNE E A, HENLEY S J, SARAIYA M, et al. Trends in human papillomavirus-associated cancers-United States, 1999-2015[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(33): 918-924.
[11] GIEN L T, BEAUCHEMIN M C, THOMAS G. Adenocarcinoma: a unique cervical cancer[J]. Gynecol Oncol, 2010, 116(1): 140- 146.
[12] RIDDELL A, MCBRIDE M, BRAUN T, et al. RUNX1: an emerging therapeutic target for cardiovascular disease[J]. Cardiovasc Res, 2020, 116(8): 1410-1423.
[13] TAHIROV T H, INOUE-BUNGO T, MORII H, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta[J]. Cell, 2001, 104(5): 755-767.
[14] MIYOSHI H, SHIMIZU K, KOZU T, et al. T(8；21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1[J]. Proc Natl Acad Sci USA, 1991, 88(23): 10431-10434.
[15] LU C H, YANG Z Y, YU D Y, et al. RUNX1 regulates TGF-β induced migration and EMT in colorectal cancer[J]. Pathol Res Pract, 2020, 216(11): 153142.
[16] HÄNZELMANN S, CASTELO R, GUINNEY J. GSVA gene set variation analysis for microarray and RNA-seq data[J]. BMC Bioinformatics, 2013, 14: 7.
[17] LIBERZON A, BIRGER C, THORVALDSDÓTTIR H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection[J]. Cell Syst, 2015, 1(6): 417-425.
[18] LI T W, FU J X, ZENG Z X, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-W514.
[19] GULLUNI F, MARTINI M, DE SANTIS M C, et al. Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2α scaffolding function[J]. Cancer Cell, 2017, 32(4): 444-459.e7.
[20] SHEN D Y, XIA Y W, FU Y H, et al. Hedgehog pathway and cancer: a new area (Review)[J]. Oncol Rep, 2024, 52(3): 116.
[21] ZHAO M, MISHRA L, DENG C X. The role of TGF-β/SMAD4 signaling in cancer[J]. Int J Biol Sci, 2018, 14(2): 111-123.
[22] SONG P, GAO Z R, BAO Y G, et al. Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy[J]. J Hematol Oncol, 2024, 17(1): 46.
[23] HERNÁNDEZ BORRERO L J, EL-DEIRY W S. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(1): 188556.
[24] WANG Y L, WU W R, LIN P L, et al. The functions of PCNA in tumor stemness and invasion[J]. Int J Mol Sci, 2022, 23(10): 5679.
[25] NOVAK D, HÜSER L, ELTON J J, et al. SOX2 in development and cancer biology[J]. Semin Cancer Biol, 2020, 67(Pt 1): 74-82.
[26] LIN T C. RUNX1 and cancer[J]. Biochim Biophys Acta BBA Rev Cancer, 2022, 1877(3): 188715.
[27] LIEW P X, KUBES P. The neutrophil’s role during health and disease[J]. Physiol Rev, 2019, 99(2): 1223-1248.

Expression of RUNX family transcription factor 1 and its prognostic value in cervical adenocarcinomas

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XIAO Huanqin, XIE Shoucheng, ZHONG Ying, LUO Wenjuan, HUANG Yanfang, LUO Haiyan, YU Qiuzhu, ZHU Wenbiao. ZMYND8 as a novel diagnostic and prognostic biomarker for glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 52-55,62.
[2]	GUO Xujuan, JIA Yuming, YAN Xi, ZHAO Hongzheng, GUO Yiyang, ZHANG Jinyan. Clinical value of CST4 in auxiliary diagnosis and prognosis assessment of pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 463-469.
[3]	KANG Xiaopei, GUO Zhenjiang, LIU Fangzhen. The expression and prognosis of BAF57 in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(5): 379-383.
[4]	ZHU Wenbiao, YAN Chunmei, QIU Bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression of secreted frizzled-related protein 4 in hepatocellular carcinoma, and relationship with clinicopathological index and prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 288-293,297.
[5]	MA Sheng, WANG Xijun, LIU Zhenrong, WANG Yaru, HU Nan, RONG Weiqi, XIAO Ting. The expression and clinical significance of MFSD2A in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 187-194.
[6]	ZHANG Yi, GAO Han, ZHENG Zhanyue, TAN Qitao, YANG Minli, SUN Yan. Screening of key genes for prognosis of glioma based on public databases [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 195-201.
[7]	SONG Zhenming, YU Yunliang, YANG Jinmei, LIU Kun, GAI Chanchan, MA Chunyu. Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 208-218.
[8]	FU Yongqing, XU Sanhui, ZHAO Yan, WANG Lili. Relationships between SPP1, DEC1, C1QTNF6 and clinicopathologic outcomes of oral squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 107-111,117.
[9]	TONG Jing, WANG Dan. Expression and significance of miR-544a in patients with colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 124-128,137.
[10]	XUE Song, HU Jiahai, DONG Xiangning. Expression of PGAM5 and its association with clinicopathologic characteristics in pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 29-34.
[11]	WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.
[12]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[13]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[14]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[15]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.